Indirubin, a traditional Chinese medicine, is used to treat autoimmune diseases in clinics. However, the effects of indirubin on the immunosuppressive CD4 
Introduction
Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by persistent thrombocytopenia in children, caused by the production of anti-platelet autoantibody against platelet membrane glycoproteins which mediates the destruction of platelets in the reticuloendothelial system, especially in the spleen [1] . It has been reported that decreased number and/or function of CD4 + CD25 + Foxp3 + regulatory T (Treg) cells, which are crucial for self-tolerance, represent one possible mechanism leading to the development of ITP [2, 3] . Indirubin is a traditional Chinese medicine currently used for the treatment of chronic myelocytic leukemia [4] and certain autoimmune conditions and anti-inflammatory therapy [5, 6] . Indirubin is a potent cyclin-dependent kinases (CDKs) and glycogen synthetase kinase 3 (GSK-3) inhibitor and suppresses tumor necrosis factor (TNF)-induced NF-κB activation [7] . However, the effects of indirubin on the immunosuppressive CD4 + CD25 + Treg cells have not been addressed. In the present study, we investigated the effect of indirubin on CD4 + CD25
+-Treg cells in experimental ITP mice.
Materials and Methods Animals
Six-to-eight weeks old female CBA mice were purchased from Model Animal Research Center (Najing, China). Wistar rats were obtained from The Laboratory Animal Center Academy of Military Medical Sciences Genetics (Jinan, China). Mice were maintained for 2 weeks prior experimentation in a specific pathogen-free(SPF) animal facility and were housed in macroisolator cages containing sterilized feed, autoclaved bedding, and water at 20 temperature and 40% humidity condition in the Experimental Animal Centre of Qilu Hospital Shandong University. All the experimental procedures were approved by the Animal Care and Use Committee of Qilu Hospital and conducted under the guidelines for Animal Care and Use of Shandong University, China. All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.
Monoclonal antibodies (mAbs) and reagents
The following mAbs were purchased from BD Biosciences PharMingen (San Diego, CA): FITC-labeled rat anti-mouse CD25 mAb (7D4; IgM), Fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD4 mAb (RM4-5; rat IgG2a), FITC-labeled anti-mouse CD8 mAb (53-6.7; rat IgG2a), phycoerythrin (PE)-labeled rat anti-mouse CD4 mAb(clone GK1.5), PElabeled anti-mouse CD25 mAb, and PE-labeled anti-mouse CD8α mAb (53-6.7; rat IgG2a). In addition, PE-labeled anti-mouse Foxp3 mAb (FJK-16s) and its staining kit were obtained from eBiosciences (San Diego, CA). The culture medium used in the present study was RPMI 1640 (Hyclone, Logan, UT) supplemented with 10% heat-inactivated FCS (Hyclone, Logan, UT), 100U/ml penicillin, 100μg/ ml streptomycin, 2mM L-glutamine, 10mM HEPES, 1mM sodium pyruvate and 50μM 2-ME (Sigma, St. Louis, MO). DMSO was obtained from Promega Co, Ltd (USA). BSA was purchased from Zhongshan Biotec Co, Ltd (Beijing, China 
Establishment of ITP animal model
Platelets were isolated from Wistar rat as Musaji described [8] . In brief, blood was collected from jugular vein of Wistar rats with 1/6 volume ACD (citrate-dextrose solution, SigmaAldrich, Bornem, Belgium). Platelet-rich supernatant was prepared by successive centrifugations at 10°C for 10 minutes at 200g. Platelets were pelleted from this supernatant by additional centrifugation at 10°C for 12 minutes at 1700g and washed as appropriate. CBA mice were divided into three groups which are control and ITP model group with/without indirubin treatment respectively (n = 10). The two group mice for ITP model were first administered with rat platelets 10 8 in 0.5 ml saline intraperitoneally, followed by an injection of 0.5×10 
Spelnocyte preparation
After mice received indirubin treatment for six weeks, all of the mice were sacrificed by CO 2 narcosis plus cervical dislocation, spleens was harvested. Single cell suspensions were prepared by grinding the tissues with the plunger of a 5 ml disposable syringe [9] . Cells then were treated with 2 ml hemolysis buffer (17mM Tris-HCl and 140mM NH4Cl, pH7.2) in 1.5-2 min to remove red blood cells. After washed in PBS, the cells were counted and split for FCM staining.
Immunofluorescence staining and flow cytometry 100μl 1×10 7 /ml Splenocytes were incubated with 2.4G to block FcRs and then incubated with optimal concentration of fluorochrome-labeled mAbs for 30 minutes at 4°C in dark [10] . Cells were washed three times and resuspended by FCM buffer (PBS with 0.1% BSA and 0.1%NaN 3 ). At least ten thousand cells were assayed using a FASCalibur flow cytometry (Becton Dickinson, CA), and data were analyzed with CellQuest software (Becton Dickinson, Mountain View, CA). In some experiments, non-viable cells were excluded using the vital nucleic acid stain propidium iodide (PI).
For the staining of intracellular Foxp3, cells were incubated with Cy-chrome-labeled anti-CD4 and FITC-labeled anti-CD25 mAbs first [11] . Then these cells were fixed after washing and stained with anti-mouse Foxp3 mAb, on the basis of the instruction provided by the company (eBioscience, San Diego, CA). 
Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed as previously described [13] . Serum levels of INFγ, IL-10 and TGF-β were measured using a commercial ELISA assay kit (BioLegend, San Diego, CA, USA) according to the manufacturer's instructions.
Statistical analysis
All data are analyzed by SPSS statistic software and presented as the mean±SD. Student's unpaired t test for comparison of means was used to compare groups. P<0.05 was considered to be statistically significant.
Results

Indirubin ameliorates transient thrombocytopenia in mice immunized with Wistar platelets
To investigate whether indirubin treatment could prevent the occurrence of ITP caused by immunization with rat platelets in CBA mice, which is a well-established ITP mouse model [14] . CBA mice pretreated or not with 50 mg/kg indirubin daily one week before immunization with rat platelets (10 8 in 0.5 ml saline) intraperitoneally, followed by 0.5×10 8 platelets weekly.
In this model, the platelet counts gradually decreased and reached to the bottom at the third week after the first immunization. At the sixth week, the platelet number returned to the normal level. However, the decrease of platelet numbers was significantly ameliorated in ITP mice with indirubin pretreatment (P<0.01, Fig 1) . In line with this observation, the level of antiplatelet autoantibody was also decreased as determined by FCM. Thus, indirubin treatment inhibits the anti-platelet autoantibody production induced by rat platelets administration and subsequently prevents the occurrence of ITP. T cells in PBLs was comparable among these mice (Fig 2A) . Interestingly, the percentage of CD4 + CD25 + Treg cells was significantly increased in indirubin-treated ITP mice as compared to that of ITP mice (P<0.01, Fig 2B and  2C) Fig 2D) . Therefore, indirubin treatment enhanced the level of CD4 + CD25 + Foxp3 + Treg cells in ITP mice.
Consistent with the peripheral blood, the percentage and total cell number of CD4 + T cells in spleen had no significant changes in ITP mice (Fig 3A) . Fig 3C and 3D ). Foxp3, a unique transcription factor for CD4 + CD25 + Treg cells, is predominantly expressed in the CD4 + CD25 + Treg cells [17] . Therefore, the expression of Foxp3 in CD4 + CD25 + T cells in these mice was assessed.
As shown in Fig 3, immunosuppressive assay [18] . Naive CD4 + CD25 -T cells were used as responder cells as described in the materials and methods. As shown in Fig 4, Fig 4A) . Interferon gamma (IFNγ), or type II interferon, is a cytokine that is critical for innate and adaptive immunity against infections. IFNγ is an important activator of macrophages and inducer of Class II major histocompatibility complex (MHC) molecule expression. Aberrant IFNγ expression is associated with a number of auto-inflammatory and autoimmune diseases. The importance of IFNγ in the immune system stems in part from its ability to inhibit viral replication directly, and most importantly from its immunostimulatory and immunomodulatory effects. IFNγ is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by CD4 Th1 and CD8 cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops. To further determine the anti-inflammatory effect of indirubin, we isolated primary CD4+T cells (Fig 5A) Fig 5D-5G ). Therefore, indirubin might selectively increase nTreg cells in the thymus in ITP mice.
Discussion
ITP is an autoimmune bleeding disorder caused by the production of anti-platelet autoantibodies that bind to platelet membrane glycoproteins or by activation of platelet-specific cytotoxic T cells and NK cells mediating the destruction of platelets [19, 20] . Nowadays, more and more patients tend to develop chronic disease progression and are liable to long-term glycocorticoid treatment or immunosuppressive reagents administration or even splenotomy, which have many side effects and could not cure the patients and are even dangerous for life [21] . Indirubin is a traditional Chinese medicine used in clinics for the treatment of chronic myelocytic leukemia. Indirubin has the ability to inhibit numerous important protein kinases including CDKs [7] . It has been demonstrated that indirubin derivatives have the potent anti-proliferative and inducing apoptosis activity in various human cancer cells [22] . Indirubin and its derivatives have also been reported to exert an anti-inflammatory effect mediated by suppression of the release of cytokine, including IFN-γ and IL-6. Treatment with indirubin derivatives also showed potent anti-proliferative activity in various human cancer cells and induced the activation of caspase-7 followed by apoptosis in RK3E-ras cells [23] . In addition, it might be useful in treating Alzheimer's disease or diabetes, too [24] . In the present study, we demonstrated that indirubin has the ability to increase immunosuppressive CD4 + CD25 + Treg cells. Thus, the treatment with indirubin may be beneficial to induce immune tolerance to self and allo-graft antigens. CD4 + CD25 + Treg cells are the key players for negatively regulating immune responses [25, 26] . Foxp3 is predominantly expressed in the CD4 + CD25 + Treg cells and recognized as the key transcription factor for Treg cell development and function [27, 28] . Induced expression of Foxp3 by TGF-β in CD4 + CD25 -T cells can convert these cells into Treg cells that displayed similar phenotype and function as naturally occurring CD4 + CD25 + Treg cells [27] . A Supporting Information S1 File.
